Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clover Biopharmaceuticals Ltd. ( (HK:2197) ) has provided an update.
Clover Biopharmaceuticals Ltd. announced the termination of its exclusive agreement with Adimmune Corporation to distribute AdimFlu-S (QIS) in mainland China, effective June 30, 2025, due to material changes in market conditions. The company believes this termination will not adversely impact its operations and remains focused on advancing its RSV vaccine candidate SCB-1019, which is part of its strategic objectives.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on developing vaccines, including its proprietary RSV vaccine candidate SCB-1019, aimed at addressing respiratory health needs.
Average Trading Volume: 1,448,367
Technical Sentiment Signal: Hold
Current Market Cap: HK$337.2M
Learn more about 2197 stock on TipRanks’ Stock Analysis page.